Abstract
Aim: A retrospective evaluation of efficacy and toleration of axitinib. Patients and methods: A total of 11 patients with metastatic renal cell carcinoma previously treated by sunitinib were evaluated.
Axitinib was applied in doses 10 mg/kg twice a day. Response rate was evaluated by RECIST 1.1.
We defined two parameters: overall survival (OS) and progression free survival (PFS). Results: We described the toxicity in all patiens, predominantly grade I-II.
Three patiens were hospitalized. One patiens died of hemoptysis.
We did not described the complete remission, partial remission we desribed in 3 patients (27.2 %) and stabilization in 5 patients (45.5 %). Primary progression we finded in 3 patients (27.2 %).
The median of PFS was 13.9 months (95 % CI 4.2-14.9 měsíce). Median of OS was not reached. 1-year OS we desribed in 59 % of patiens.
Conclusion: The treatment with axitinib we evaluate positively. Axitinib is integral part of treatment in patiens with metastatic renal cell carcinoma.